Investment Thesis
Anixa Biosciences is a pre-revenue pharmaceutical company burning cash at an unsustainable rate with minimal revenue generation ($210K), negative operating margins exceeding -1200%, and persistent operating losses. Despite strong balance sheet liquidity, the company is consuming capital rapidly with no clear path to profitability, making it a high-risk speculative entity dependent on successful drug development and future financing.
ANIX Strengths
- Strong current ratio of 12.18x indicates adequate short-term liquidity to fund operations
- Low debt-to-equity ratio of 0.02x provides minimal financial leverage risk
- Substantial stockholders' equity of $15.1M provides some capital cushion for R&D investments
ANIX Risks
- Severe cash burn with negative operating cash flow of -$2.6M while generating only $210K in revenue
- Extreme negative profitability margins (-1293% operating margin, -1221% net margin) indicating substantial losses relative to minimal revenue
- High dependency on future financing and successful clinical trial outcomes with no demonstrated ability to generate sustainable revenue
- Cash runway limited to approximately 7 months at current burn rate if no additional capital is raised
Key Metrics to Watch
- Quarterly operating cash flow trend and runway duration
- Revenue growth trajectory from pipeline programs and partnerships
- Clinical trial progress and regulatory milestones for lead drug candidates
- Changes in cash balance and capital raising activities
- Operating expense management and R&D spending efficiency
ANIX Financial Metrics
ANIX Profitability Ratios
ANIX Balance Sheet & Liquidity
ANIX 5-Year Financial Trend
5-Year Trend Summary: Anixa Biosciences Inc's revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-0.39 indicates the company is currently unprofitable.
ANIX Growth Metrics (YoY)
ANIX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $210.0K | -$2.5M | $-0.08 |
| Q2 2024 | $210.0K | -$2.3M | $-0.07 |
| Q3 2023 | $210.0K | -$2.5M | $-0.08 |
| Q2 2023 | $210.0K | -$2.3M | N/A |
| Q3 2022 | $513.0K | -$2.7M | N/A |
| Q2 2022 | $513.0K | -$2.4M | N/A |
| Q1 2022 | $513.0K | -$2.2M | N/A |
| Q3 2021 | $512.5K | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ANIX Capital Allocation
ANIX SEC Filings
Access official SEC EDGAR filings for Anixa Biosciences Inc (CIK: 0000715446)